Table 5 |
||||||||
|
Association between XRCC1 condon 194 and 399 polymorphisms and NPC risk stratified by age range (yr) |
||||||||
|
Genotype |
<60 |
≥60 |
||||||
|
|
||||||||
|
Cases |
Controls |
Adjusted ORa (95% CI) |
P value |
Cases |
Controls |
Adjusted ORa (95%CI) |
P value |
|
|
|
||||||||
|
XRCC1 Arg194Trp |
||||||||
|
Arg/Arg |
189 |
190 |
1.00 |
42 |
45 |
1.00 |
||
|
Arg/Trp |
151 |
179 |
0.85(0.62–1.16) |
0.30 |
17 |
38 |
0.48(0.23–0.99) |
0.05* |
|
Trp/Trp |
17 |
37 |
0.52(0.28–0.96) |
0.04 |
1 |
6 |
0.27(0.03–2.52) |
0.25 |
|
XRCC1 Arg399Gln |
||||||||
|
Arg/Arg |
210 |
228 |
1.00 |
27 |
42 |
1.00 |
||
|
Arg/Gln |
131 |
159 |
0.83(0.61–1.13) |
0.23 |
25 |
41 |
0.84(0.38–1.86) |
0.67 |
|
Gln/Gln |
22 |
25 |
1.09(0.58–2.05) |
0.79 |
10 |
6 |
1.75(0.48–6.44) |
0.40 |
|
|
||||||||
|
aAdjust OR were calculated with the XRCC1 194Arg/Arg or 399Arg/Arg genotype as the reference group and adjusted for sex, smoking status. *P-value was not significant after Bonferroni's correction. |
||||||||
|
Cao et al. BMC Cancer 2006 6:167 doi:10.1186/1471-2407-6-167 |
||||||||
